Please login to the form below
oral anticoagulant
This page shows the latest oral anticoagulant news and features for those working in and with pharma, biotech and healthcare.
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... However, BMS is facing competition from generic rivals of Eliquis – in December 2019, the FDA approved
Latest news
-
FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis
These approvals mark the first generic approvals of a direct oral anticoagulant,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). ... Unlike older anticoagulants like warfarin, “direct oral
-
Pfizer CEO reckons rebates will disappear, and that’s a positive
its innovative health unit and particularly Xeljanz – up 38% to $463m in the quarter – as well as breast cancer drug Ibrance (palbociclib) which rose 20% to $1bn and novel oral anticoagulant
-
Pharma sales help Bayer escape the worst from a bumpy 2017
Its pharma business was once again led by Bayer’s top-seller Xarelto, with sales of the oral anticoagulant rising 12.6% to 3.6bn, and eye drug Eylea, which was
-
Bad news for Portola as CHMP considers Factor Xa drugs
Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... for betrixaban, its oral, once-daily Factor Xa inhibitor, as well as antidote drug andexanet alfa.
-
Joerg Moeller to head Bayer R&D after operational shake-up
It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase
More from news
Approximately 0 fully matching, plus 78 partially matching documents found.
Latest Intelligence
-
Digital disruption in market access
publication of the first direct oral anticoagulant technology appraisal, we are not yet there.
-
Modern anticoagulants threaten status quo
Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Delays and withdrawals. Eli Lilly was developing a once-daily, piperazine class, oral anticoagulant called LY 517717
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Europe’s cancer community publishes new report on transforming patient care
- Assessing the value of interim analyses in clinical trials
- Piloting a route to the biosimilars opportunities in Europe
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
